Valneva SE announced that the first participant has been vaccinated in the Phase 2 clinical trial evaluating the safety and Immunogenicity in children of two different dose levels of Valneva’s Single-shot Chikungunya Vaccine. Currently, Valneva does offer a Chikungunya vaccine for adults 18 years and older, targeting individuals who are increased risk of exposure.
In January 2021, Valneva and the Instituto Butantan in Brazil signed an agreement to develop, produce, and commercialise VLA1553, with the aim of making the vaccine more accessible to low- and middle-income countries (LMICs).
